Codexis (US:CDXS) — Company Overview, News & Financial Data
Codexis develops engineered enzymes for pharmaceuticals and bioindustrial applications, focusing on sustainability and efficiency.
Codexis
Codexis (NASDAQ:CDXS) specializes in developing engineered enzymes for pharmaceutical, bioindustrial, and diagnostic applications. The company's innovative approach to enzyme engineering enables the creation of highly optimized biocatalysts that drive efficiency and cost-effectiveness in drug manufacture, the production of bio-based chemicals, and diagnostic tests. Codexis is focused on leveraging its proprietary CodeEvolver® technology platform to accelerate the development of novel enzymes and to form strategic partnerships and collaborations across various industries. With a strong commitment to sustainability, Codexis aims to contribute to a greener and more sustainable future through its enzyme engineering advancements, targeting objectives that include expanding its enzyme product portfolio and entering new markets.
Snapshot
Operations
Products and/or services of Codexis
- Biotherapeutics: Enzyme engineering for developing novel enzymes for therapeutic applications, incorporating protein engineering for targeted drug delivery and disease treatment.
- Codex Biocatalyst Panels: Pre-engineered enzyme kits designed for pharmaceutical and chemical manufacturing, aimed at improving process efficiency and sustainability.
- CodeEvolver: A proprietary platform technology for enzyme optimization, enabling the rapid development of customized solutions for biotherapeutics, fine chemicals, and agrochemicals.
- Custom Enzyme Development Services: Tailored enzyme engineering and development services for unique industrial and pharmaceutical applications, leveraging advanced protein engineering techniques.
- Food and Nutrition Ingredients: Development of enzymes for the production of health-promoting ingredients and processing aids for the food and beverage industry.
- Life Science Tools and Services: Offering enzymes and enzyme-based kits for genomics, drug discovery, and biotherapeutic research, assisting scientific investigation and innovation.
Codexis executive team
- Dr. Alison Moore Ph.D.President, CEO & Director
- Ms. Georgia L. ErbezCFO & Chief Business Officer
- Senator Byron L. Dorgan M.B.A.Consultant
- Dr. Stefan Lutz Ph.D.Chief Scientific Officer
- Ms. Carrie McKimDirector of Investor Relations
- Mr. Britton JimenezSenior Vice President of Sales & Marketing
- Ms. Karen Frechou-ArmijoSenior VP & Head of Human Resources
- Mr. John SchiffhauerSenior Vice President of Intellectual Property